- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00886964
Hepatitis B Vaccination (HBV) in HIV Infected Children
Immunogenicity and Safety of Intradermal Compare to Intramuscular Hepatitis B Vaccination in HIV Children
The purpose of this study is :
- To evaluate prevalence of protective hepatitis B antibody comparing intradermal (ID) and intramuscular (IM) route in antiHbsAb negative HIV infected children treated with highly active antiretroviral therapy (HAART)
- To revaccinate the HBV vaccine in the children who didn't have protective HBV Ab
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Hepatitis B virus (HBV) and HIV share the same route of transmission and can have co-infection. The prevalence of this co-infection was 8.7% in Thai adult[1, 2] and 12.1% in African HIV vertically transmitted children[3]. Occurrence of HBV has effects to treatment due to having the same medication, lamivudine, tenofovir, emtricitabine or entecavir, to anti HIV medication. HBV can cause chronic liver disease, cirrhosis and hepatocellular carcinoma.
In Thailand, the routine HBV vaccination program was started since 1992. Few reports in severe immune compromise HIV children has been shown to lose their expected preventive measles and hepatitis B antibody from history of scheduled vaccination even after the immune recovery by HAART[4, 5]. Limited data in of prevalence of protective hepatitis B antibody response after immune recovery in Thai HIV infected children treated with highly active antiretroviral therapy. In addition, HBV revaccination in this group of children should be considered[6].
The response of HBV revaccination intramuscularly (IM) at 0, 2 and 6 months in 63 HIV children shown response rates 17.4, 82.5, and 92.1% at 2, 6 and 7 months respectively[6]. Protective anti-HBs were shown in the majority of non-responders to IM HBV vaccine health care workers [21/23 (91.3%)] by two doses of intradermal route (ID)[7].
We hypothesize to see the faster and higher response of antiHBs after first dose of ID compare to IM in anti HBsAb negative HIV infected children. No randomized control trial compare antibody response between IM and ID route in HIV children after immune recovery. The benefit from this trial would be decreased the vaccine cost for resourced limited country.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Bangkok, Thailand, 10330
- HIV-NAT
-
Bangkok, Thailand, 10330
- Pediatric infectious diseases section, King Chulalongkorn Memorial hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- HIV infected individuals
- Age 1-18 years
- Current CD4 within 6 months ≥ 15% or ≥ 200 cells/ml in children age ≥ 6 years
- Signed written informed consent
- Negative HBs Ag, antiHBs, and antiHBc at screening visit
Exclusion Criteria:
- Active AIDS
- Active opportunistic infection
- Platelet < 50,000/ mm3 at screening visit
- History of hypersensitivity to HBV vaccine
- Using oral steroid or immunosuppressive drugs
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: 1
HBV ID
|
Dosage: 2 microgram (mcg), 0.1 ml per dose Location: left deltoid area x 1 injection Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months |
Aktiv komparator: 2
HBV IM
|
Dosage: 2 microgram (mcg), 0.1 ml per dose Location: left deltoid area x 1 injection Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Proportion of children with protective antiHBs at 8 weeks after first dose of HBV ID is superior to HBV IM
Tidsramme: 8 weeks
|
8 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Proportion of children with positive antiHBs at 4 weeks after second and third dose of HBV
Tidsramme: 4 weeks
|
4 weeks
|
Number of adverse events in HBV ID group and HBV IM group
Tidsramme: 7 months
|
7 months
|
Proportion of protective antiHBs in HIV children after protocol defining immune recovery
Tidsramme: 7 months
|
7 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Torsak Bunupuradah, MD, The Hiv Netherlands Australia Thailand Research Collaboration
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HIV-NAT 107
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV-infeksjoner
-
Universidad del DesarrolloFullførtHealthcare Associated InfectionChile
-
Imelda Hospital, BonheidenFullførtHealthcare Associated InfectionBelgia
-
Centre Hospitalier Universitaire de NīmesRekrutteringEldre | Healthcare Associated InfectionFrankrike
-
Centre Hospitalier Universitaire, AmiensFullførtHealthcare Associated Infection | IglerFrankrike
-
Johns Hopkins UniversityFullførtHealthcare Associated Infection | Multiresistente organismer
-
University of PennsylvaniaFullførtAntimikrobiell resistensForente stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentFullførtMenneskelig mikrobiomForente stater
-
Universidad Autonoma de Nuevo LeonUkjentHelsetilknyttede infeksjoner
-
Children's Hospital Medical Center, CincinnatiAvsluttetAllogen hematopoetisk celletransplantasjonForente stater
-
Central Hospital, Nancy, FranceHar ikke rekruttert ennåHealthcare Associated Infection | Antibiotika
Kliniske studier på Intradermal HBV 1 course
-
Seoul National University HospitalAvsluttetHepatitt B-vaksinasjonKorea, Republikken
-
Merck Sharp & Dohme LLCFullført
-
SanofiFullførtInfluensa | Myxovirus infeksjonForente stater
-
I.M. Sechenov First Moscow State Medical UniversityNanoPass Technologies LtdFullført
-
GlaxoSmithKlineFullførtHepatitt B | Tetanus | Difteri | Acellulær Pertussis | Poliomyelitt | Haemophilus Influenzae Type bFinland, Den dominikanske republikk
-
Teva Branded Pharmaceutical Products R&D, Inc.FullførtParkinsons sykdomForente stater
-
Merck Sharp & Dohme LLCAvsluttet
-
GlaxoSmithKlineFullførtInfeksjoner, streptokokkerTyskland, Tsjekkia, Sverige, Polen
-
Plan Nacional sobre el Sida (PNS)Effice Servicios Para la Investigacion S.L.FullførtKoronavirusinfeksjonSpania
-
Healeon Medical IncTerry, Glenn C., M.D.; Ministry of Health, Honduras; Robert W. Alexander, MDPåmelding etter invitasjon